Document is current
Any future updates will be listed below
-
Authors
Verhoef, Lisanne https://orcid.org/0000-0001-9877-0297
Bleeker, Maaike C. G.
Polman, Nicole
Steenbergen, Renske D. M.
Ebisch, Renée M. F.
Melchers, Willem J. G.
Bekkers, Ruud L. M. https://orcid.org/0000-0002-4577-8495
Molijn, Anco C.
Quint, Wim G.
van Kemenade, Folkert
Meijer, Chris J. L. M. https://orcid.org/0000-0002-2758-9463
Berkhof, Johannes
Heideman, Daniëlle A. M. https://orcid.org/0000-0001-6463-7391
- License Information
-
More Information
Article History
Received: 29 August 2022
Revised: 4 April 2023
Accepted: 12 April 2023
First Online: 26 April 2023
Competing interests
: DAMH, RDMS and CJLMM are minority shareholders of Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc; Self-screen B.V. develops, manufactures and licences high-risk HPV and methylation marker assays for cervical cancer screening and holds patents on these tests; JB had financial support from the European Commission (RISCC, grant number 847845); CJLMM is part-time CEO of Self-screen B.V., and has a very small number of shares of MDXHealth and previously QIAGEN, has received speakers fees from GSK, QIAGEN and SPMSD/Merck, and served occasionally on the scientific advisory boards of these companies; LV, MCGB, NP, RMFE, WJGM, RLMB, ACM, WGQ and FJvK declare no competing interests.
: The work in this study with human-derived material was conducted under national and international rules and legislations and in accordance with the Declaration of Helsinki. The study was approved by the Medical Ethics Committee of Amsterdam UMC, Vrije Universiteit Amsterdam (Amsterdam, The Netherlands; METC 2018/09, TcB 2018.106). The IMPROVE study was approved by the Ministry of Public Health (The Hague, The Netherlands; IMPROVE VWS no. 2014/32). All participants provided written informed consent.
: Not applicable.
